Top-News
Pharmazeutika USA

Nektar Therapeutics Inc News

Aktie
WKN:  165417 ISIN:  US6402681083 US-Symbol:  NKTR
1,536 €
+0,019 €
+1,25%
27.05.24 20:55:29
Handeln Depot/Watchlist
Aktienanzahl *
183,62 Mio.
Marktkapitalisierung *
277,34 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 06.05.2024

Nektar Therapeutics Inc News

09.05.24 - PR Newswire
Nektar Therapeutics Reports First Quarter 2024 Financial Results
Nektar Therapeutics Reports First Quarter 2024 Financial Results PR Newswire
02.05.24 - PR Newswire
Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets
Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets PR Newswire
22.03.24 - PR Newswire
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference PR Newswire
05.03.24 - PR Newswire
Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata
Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata PR Newswire
04.03.24 - PR Newswire
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results PR Newswire
04.03.24 - PR Newswire
Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX PR Newswire
27.02.24 - PR Newswire
Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference
Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference PR Newswire
26.02.24 - PR Newswire
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets
Nektar to Announce Financial Results for the Fourth Quarter and Year-​Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets PR Newswire
03.01.24 - PR Newswire
Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA PR Newswire
11.12.23 - PR Newswire
Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting
Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual ...
07.11.23 - PR Newswire
Nektar Therapeutics Reports Third Quarter 2023 Financial Results
Nektar Therapeutics Reports Third Quarter 2023 Financial Results PR Newswire
31.10.23 - PR Newswire
Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets
Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets PR Newswire
13.10.23 - PR Newswire
Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress
Nektar Presents New Responder Data for Rezpegaldesleukin, a First-​in-Class Selective Regulatory T-cell Therapy, in Late-​Breaking News Oral Presentation at 2023 EADV ...
02.10.23 - PR Newswire
Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy
Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-​in-Class Selective Regulatory T-cell Therapy PR Newswire
27.09.23 - PR Newswire
Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer
Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small ...
13.09.23 - PR Newswire
Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-​to-Severe Atopic Dermatitis PR Newswire
06.09.23 - PR Newswire
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th PR Newswire
08.08.23 - PR Newswire
Nektar Therapeutics Reports Second Quarter 2023 Financial Results
Nektar Therapeutics Reports Second Quarter 2023 Financial Results PR Newswire
07.08.23 - PR Newswire
Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company
Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli ...
01.08.23 - PR Newswire
Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets
Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets PR Newswire

Newssuche

Videos

27.05.24 -13,44%
Technical Trading: Copper Short Chance
Copper Short Typ: Turbo Open End WKN: VQ7PJR Hebel: 9,92 Laufzeit: OpenEnd Einstieg: Market ... Mehr »